Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Feb;8(1):57-62.
doi: 10.4300/JGME-D-15-00137.1.

Interpreting Clinical Trial Outcomes for Optimal Patient Care: A Survey of Clinicians and Trainees

Interpreting Clinical Trial Outcomes for Optimal Patient Care: A Survey of Clinicians and Trainees

Tanner J Caverly et al. J Grad Med Educ. 2016 Feb.

Abstract

Background: Evaluation of the clinical importance of outcomes in research studies is an essential element of clinical decision making.

Objective: To understand how clinicians and trainees weigh the importance of different types of clinical outcomes in drug trials.

Methods: A self-administered paper survey contained 4 scenarios asking participants to rate (1, "no proof" to 10, "good proof") the extent to which 4 study outcomes provided "proof that the new drug might help people." Outcomes included (1) a surrogate outcome; (2) a surrogate-enriched composite outcome; (3) stroke mortality; and (4) all-cause mortality. The primary study metrics were mean ratings for each of the 4 outcome types, and the proportion ranking outcome importance of all-cause mortality > stroke mortality > surrogate-enriched composite or surrogate alone.

Results: A convenience sample of 549 clinicians and trainees at 2 medical centers completed the survey (response rate: 87% medical students, 80% internal medicine residents, 69% general medicine faculty, and 41% physician experts). The surrogate-enriched composite outcome and stroke mortality were rated the most important evidence for benefit (6.6 and 6.4, respectively), with all-cause mortality and a surrogate outcome being rated significantly lower (5.2 and 4.6, respectively). In addition, 48% of clinicians rated improvement in all-cause mortality as more valuable than an improvement in a surrogate marker. Only 21% rated all-cause mortality as more valuable than a surrogate-enriched composite outcome.

Conclusions: These findings raise concerns that clinicians and trainees may not interpret trial evidence in a way that promotes the best care for patients.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: The authors declare they have no competing interests.

Figures

FIGURE
FIGURE
Combined Probability of Ranking 3, 4, or 5 Comparisons Correctlya by Clinical Background and Statistical Numeracy a “Correctly” defined by the following pairwise rankings: stroke mortality > surrogate; all-cause mortality > surrogate; stroke mortality > composite; all-cause mortality > composite; and all-cause mortality > stroke mortality. The combined probability of answering 3, 4, or 5 pairwise comparisons “correctly” is presented (ie, “majority correct”). bP < .05 in the ordinal logistic regression model.

Comment in

References

    1. Woloshin W, Schwartz LM, Welch HG. Know Your Chances: Understanding Health Statistics. 1st ed. Berkeley: University of California Press;; 2008. - PubMed
    1. Guyatt G. JAMA's Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice. New York, NY: McGraw-Hill Medical;; 2008.
    1. Cordoba G, Schwartz L, Woloshin S, Bae H, Gotzsche PC. Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review. BMJ. 2010;341:c3920. - PMC - PubMed
    1. Ferreira-Gonzalez I, Permanyer-Miralda G, Domingo-Salvany A, Busse JW, Heels-Ansdell D, Montori VM, et al. Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials. BMJ. 2007;334(7597):786. - PMC - PubMed
    1. Black WC, Haggstrom DA, Welch HG. All-cause mortality in randomized trials of cancer screening. J Natl Cancer Inst. 2002;94(3):167–173. - PubMed

Publication types